OS Therapies Incorporated (AMEX:OSTX) Financings

OS Therapies Incorporated

Financings

RaiseDate
Debt financing
Tranche closed: US$5M raised
Aug 17, 2026
Warrant exercise of common stock purchase warrants exercised or pre-funded for cash under warrant inducement
Announced: US$7.53M · Ceros Capital Markets, a division of Ceros Financial Services, Inc.
Dealers: Ceros Capital Markets, a division of Ceros Financial Services, Inc. (lead)
Use of proceeds: OST-HER2 regulatory filings and commercial preparation, OS Animal Health spinoff preparations, and general corporate purposes
Jan 12, 2026
Warrant exercise of outstanding warrants with $1.12 exercise price exercised under warrant inducement and exchange offer
Closed: US$3.7M raised · US$1.12 a share · Warrants at US$3 · Ceros Financial Services, Inc.
Dealers: Ceros Financial Services, Inc. (lead)
Use of proceeds: Primarily to accelerate OST-HER2 commercial launch preparations in osteosarcoma in the United States
Sep 2, 2025
Shares under Equity Purchase Agreement (equity line of credit)
Cancelled: raise
Buyers: Square Gate Capital Master Fund, LLC — Series 3
Aug 26, 2025
At-the-market programme of common stock
Announced: up to US$18M · B. Riley Securities +1
Dealers: B. Riley Securities, JonesTrading
Aug 19, 2025
Warrant exercise of warrants exercised under warrant exercise inducement and exchange offer
Closed: US$1.76M raised · US$1.12 a share · Warrants at US$3 for 60 months
Use of proceeds: Regulatory and pre-commercial work for OST-HER2 approvals, OS Animal Health alternatives, OST-504 study close-out, AI tADC modeling, general corporate
Jul 14, 2025

Read by 6ix AI from the company's releases